269 related articles for article (PubMed ID: 12482941)
1. A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.
Black KJ; Hershey T; Koller JM; Videen TO; Mintun MA; Price JL; Perlmutter JS
Proc Natl Acad Sci U S A; 2002 Dec; 99(26):17113-8. PubMed ID: 12482941
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease.
Piercey MF
Clin Neuropharmacol; 1998; 21(3):141-51. PubMed ID: 9617505
[TBL] [Abstract][Full Text] [Related]
3. The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats.
Koffarnus MN; Greedy B; Husbands SM; Grundt P; Newman AH; Woods JH
Psychopharmacology (Berl); 2009 Apr; 203(2):317-27. PubMed ID: 18807248
[TBL] [Abstract][Full Text] [Related]
4. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats.
Lagos P; Scorza C; Monti JM; Jantos H; Reyes-Parada M; Silveira R; Ponzoni A
Eur Neuropsychopharmacol; 1998 May; 8(2):113-20. PubMed ID: 9619689
[TBL] [Abstract][Full Text] [Related]
5. Excitation of type II anterior caudate neurons by stimulation of dopamine D3 receptors.
Piercey MF; Hyslop DK; Hoffmann WE
Brain Res; 1997 Jul; 762(1-2):19-28. PubMed ID: 9262154
[TBL] [Abstract][Full Text] [Related]
6. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
7. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
Siuciak JA; Fujiwara RA
Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.
Piercey MF; Hoffmann WE; Smith MW; Hyslop DK
Eur J Pharmacol; 1996 Sep; 312(1):35-44. PubMed ID: 8891576
[TBL] [Abstract][Full Text] [Related]
9. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain.
Chernoloz O; El Mansari M; Blier P
J Psychiatry Neurosci; 2012 Feb; 37(2):113-21. PubMed ID: 22023785
[TBL] [Abstract][Full Text] [Related]
10. Effects of pramipexole on the processing of rewarding and aversive taste stimuli.
McCabe C; Harwood J; Brouwer S; Harmer CJ; Cowen PJ
Psychopharmacology (Berl); 2013 Jul; 228(2):283-90. PubMed ID: 23483198
[TBL] [Abstract][Full Text] [Related]
11. Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.
Kitagawa K; Kitamura Y; Miyazaki T; Miyaoka J; Kawasaki H; Asanuma M; Sendo T; Gomita Y
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jul; 380(1):59-66. PubMed ID: 19274453
[TBL] [Abstract][Full Text] [Related]
12. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum.
Piercey MF; Walker EL; Feldpausch DL; Camacho-Ochoa M
Neurosci Lett; 1996 Nov; 219(2):138-40. PubMed ID: 8971799
[TBL] [Abstract][Full Text] [Related]
13. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
[TBL] [Abstract][Full Text] [Related]
14. Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
Filip M; Papla I
Pol J Pharmacol; 2001; 53(6):577-85. PubMed ID: 11985331
[TBL] [Abstract][Full Text] [Related]
15. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
[TBL] [Abstract][Full Text] [Related]
16. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
[TBL] [Abstract][Full Text] [Related]
17. Low dose pramipexole causes D3 receptor-independent reduction of locomotion and responding for a conditioned reinforcer.
McCormick PN; Fletcher PJ; Wilson VS; Browne JD; Nobrega JN; Remington GJ
Neuropharmacology; 2015 Feb; 89():225-31. PubMed ID: 25283483
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.
Bennett JP; Piercey MF
J Neurol Sci; 1999 Feb; 163(1):25-31. PubMed ID: 10223406
[TBL] [Abstract][Full Text] [Related]
19. Food restriction alters N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride (pramipexole)-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects.
Collins GT; Calinski DM; Newman AH; Grundt P; Woods JH
J Pharmacol Exp Ther; 2008 May; 325(2):691-7. PubMed ID: 18305018
[TBL] [Abstract][Full Text] [Related]
20. Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [
Schneier FR; Slifstein M; Whitton AE; Pizzagalli DA; Reinen J; McGrath PJ; Iosifescu DV; Abi-Dargham A
Biol Psychiatry; 2018 Oct; 84(8):563-573. PubMed ID: 30041971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
